Target- |
MechanismStem cell replacements |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 2 An Open Label Study of STR04 in Participants With Amyotrophic Lateral Sclerosis
This study intends to evaluate the safety and efficacy of STR04 administered intravenously in participants with Amyotrophic Lateral Sclerosis.
100 Clinical Results associated with New England Cell Therapeutics, Inc.
0 Patents (Medical) associated with New England Cell Therapeutics, Inc.
100 Deals associated with New England Cell Therapeutics, Inc.
100 Translational Medicine associated with New England Cell Therapeutics, Inc.